Premium
Elevation of gastric pH with ranitidine does not affect the release characteristics of sustained release ibuprofen tablets
Author(s) -
Berardi Rosemary R.,
Dressman Jennifer B.,
Elta Grace H.,
Szpunar Gregory J.
Publication year - 1988
Publication title -
biopharmaceutics and drug disposition
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.419
H-Index - 58
eISSN - 1099-081X
pISSN - 0142-2782
DOI - 10.1002/bod.2510090403
Subject(s) - ibuprofen , ranitidine , chemistry , crossover study , pharmacology , stomach , medicine , chromatography , biochemistry , alternative medicine , pathology , placebo
Abstract The effect of elevating gastric pH on the release characteristics of a single unit sustained release (SR) ibuprofen tablet (MOTRIN‐SR®, Upjohn) was evaluated in 12 young, healthy men. Using a randomized crossover‐type design, each subject received three treatments – ibuprofen SR 800 mg, ranitidine 300 mg followed by ibuprofen SR 800 mg, and conventional ibuprofen tablets (2 × 400 mg). Gastric pH, which was monitored radiotelemetrically, was maintained above pH 6 for at least 4 h after pretreatment with ranitidine. In absence of ranitidine, the pH remained mostly below pH 3. Serum levels of ibuprofen were measured for 24 h and urine was collected for 48 h after each treatment. Similarity of the serum levels after the two treatments with ibuprofen SR 800 mg indicated that the release of ibuprofen was unaffected by elevation in gastric pH. Comparison of profiles with the immediate release dosage form indicated that dose dumping did not occur in any subject.